Home
Search:
1146 feeds
357 categories
0 articles (<24 hours)
29 registered users

Use the Mobile version
Mobile

Follow our Twitter feed

View our Linkpartners
Links

Username:
Password:

Register | Retrieve


RSS FeedsOncopeptides presents promising data from the Phase 2 ANCHOR combination study in patients with RRMM at ASH Annual Meeting 2019
(WorldNews Business)

 
 

8 december 2019 16:35:52

 
Oncopeptides presents promising data from the Phase 2 ANCHOR combination study in patients with RRMM at ASH Annual Meeting 2019
(WorldNews Business)
 


STOCKHOLM - December 8, 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) will today present updated data from the ongoing Phase 2 ANCHOR (OP-104) triple combination study at the ASH Annual Meeting 2019. In the data presented, melflufen and dexamethasone demonstrated positive efficacy in combination with daratumumab or bortezomib in patients with relapsed/refractory multiple myeloma (RRMM). Preclinical data supporting clinical development of melflufen in AL amyloidosis will also be presented for the first time. Overall Conclusions - ANCHOR Poster Presentation Patients in the ANCHOR study had a median of two prior lines of therapy. All patients were refractory to at least one agent. For...


 
22 viewsCategory: Business
 
Metro Phoenix home prices hit record; check out valuations on Street Scout
(WorldNews Business)
Business news for Dec. 8, 2019
(WorldNews Business)
 
 
blog comments powered by Disqus


Copyright © 2008 - 2024 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures Science Tweets Nachrichten